Concepedia

Publication | Open Access

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

DOIFull Paper Access

159

Citations

17

References

2019

Year

Timothy A. Yap, Jane N. Winter, Lisa Giulino‐Roth, Jemma Longley, Juanita Lopez, Jean‐Marie Michot, John P. Leonard, Vincent Ribrag, Michael T. McCabe, Caretha L. Creasy,
Clinical Cancer Research

Abstract

The MTD of GSK2816126 was established at 2,400 mg, but the dosing method and relatively short half-life limited effective exposure, and modest anticancer activity was observed at tolerable doses.

References

YearCitations

Page 1